drug costs

Summary

Summary: The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).

Top Publications

  1. ncbi Segmented regression analysis of interrupted time series studies in medication use research
    A K Wagner
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    J Clin Pharm Ther 27:299-309. 2002
  2. ncbi The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months
    Björn Wettermark
    Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacoepidemiol Drug Saf 16:726-35. 2007
  3. ncbi Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece
    Nikolaos Maniadakis
    General University Hospital of Patras, Rion, Greece
    Hellenic J Cardiol 46:212-21. 2005
  4. pmc Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    D Huscher
    German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 65:1175-83. 2006
  5. ncbi Direct medical costs of COPD--an excess cost approach based on two population-based studies
    Petra Menn
    Institute of Health Economics and Health Care Management, Helmholtz Zentrum Muenchen, Ingolstaedter Landstr 1, 85764 Neuherberg, Germany
    Respir Med 106:540-8. 2012
  6. ncbi Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis
    Mickael Hiligsmann
    Department of Economics, University of Liege, Liege, Belgium
    Value Health 12:687-96. 2009
  7. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
  8. pmc Retail sector distribution chains for malaria treatment in the developing world: a review of the literature
    Edith Patouillard
    London School of Hygiene and Tropical Medicine, Keppel Street, London, UK
    Malar J 9:50. 2010
  9. ncbi Pharmaceutical supply chain in China: current issues and implications for health system reform
    Xuan Yu
    Department of Health Services, Fourth Military Medical University, Xi an, China
    Health Policy 97:8-15. 2010
  10. ncbi Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Alexandra Cameron
    Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    Value Health 15:664-73. 2012

Detail Information

Publications353 found, 100 shown here

  1. ncbi Segmented regression analysis of interrupted time series studies in medication use research
    A K Wagner
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    J Clin Pharm Ther 27:299-309. 2002
    ..In this paper, we show how segmented regression analysis can be used to evaluate policy and educational interventions intended to improve the quality of medication use and/or contain costs...
  2. ncbi The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months
    Björn Wettermark
    Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Stockholm, Sweden
    Pharmacoepidemiol Drug Saf 16:726-35. 2007
    ..To describe the content and potentials of the new Swedish national register on prescribed and dispensed medicines...
  3. ncbi Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece
    Nikolaos Maniadakis
    General University Hospital of Patras, Rion, Greece
    Hellenic J Cardiol 46:212-21. 2005
    ..The objective of this paper was to conduct an economic evaluation of three alternative treatment options, alteplase, reteplase, and tenecteplase, in different groups of patients...
  4. pmc Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    D Huscher
    German Rheumatism Research Centre, Berlin, Germany
    Ann Rheum Dis 65:1175-83. 2006
    ....
  5. ncbi Direct medical costs of COPD--an excess cost approach based on two population-based studies
    Petra Menn
    Institute of Health Economics and Health Care Management, Helmholtz Zentrum Muenchen, Ingolstaedter Landstr 1, 85764 Neuherberg, Germany
    Respir Med 106:540-8. 2012
    ..While it is known that severe COPD has substantial economic consequences, evidence on resource use and costs in mild disease is scarce. The objective of this study was to investigate excess costs of early stages of COPD...
  6. ncbi Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis
    Mickael Hiligsmann
    Department of Economics, University of Liege, Liege, Belgium
    Value Health 12:687-96. 2009
    ..In this article, we describe and validate an original Markov microsimulation model to accurately assess the cost-effectiveness of prevention and treatment of osteoporosis...
  7. ncbi Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire
    Sue J Goldie
    Department of Health Policy and Management, Program in Health Decision Science, Harvard School of Public Health, Boston, MA 02115, USA
    N Engl J Med 355:1141-53. 2006
    ..As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed...
  8. pmc Retail sector distribution chains for malaria treatment in the developing world: a review of the literature
    Edith Patouillard
    London School of Hygiene and Tropical Medicine, Keppel Street, London, UK
    Malar J 9:50. 2010
    ..This article presents the findings of a systematic literature review on the retail sector distribution chain for malaria treatment in low and middle-income countries...
  9. ncbi Pharmaceutical supply chain in China: current issues and implications for health system reform
    Xuan Yu
    Department of Health Services, Fourth Military Medical University, Xi an, China
    Health Policy 97:8-15. 2010
    ..This article discusses the performance and distortions of pharmaceutical market in China and provides some reflections and policy implications for currently implemented reform...
  10. ncbi Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Alexandra Cameron
    Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    Value Health 15:664-73. 2012
    ..We estimated the savings that could be obtained from a hypothetical switch in medicine consumption from originator brands to lowest-priced generic equivalents for a selection of medicines in 17 countries...
  11. ncbi Assessing efficiency and costs of scaling up HIV treatment
    Susan M Cleary
    Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
    AIDS 22:S35-42. 2008
    ..This paper proposes an approach to simultaneously assessing both factors when setting priorities for HIV treatment...
  12. ncbi Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures
    O Sheehy
    Pharmacoeconomics and Pharmacoepidemiology, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    Osteoporos Int 20:1583-94. 2009
    ..Of particular interest are the amounts of money wasted by patients who did not take their BPs long enough to obtain a clinical benefit...
  13. pmc A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops
    Justin M Cohen
    Clinton Health Access Initiative, 383 Dorchester Ave, Boston MA, 02127, USA
    BMC Health Serv Res 10:S6. 2010
    ..The Government of Tanzania and the Clinton Foundation piloted this subsidized distribution model in two Tanzanian districts to examine concerns about whether the intervention will successfully reach poor, rural communities...
  14. ncbi Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization
    D W Mapel
    Epidemiology and Cancer Control Program, University of New Mexico Health Sciences Center, 2325 Camino de Salud NE, Albuquerque, NM 87131 5306, USA
    Arch Intern Med 160:2653-8. 2000
    ....
  15. ncbi Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
    ..Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution...
  16. ncbi The challenge of biosimilars
    H Mellstedt
    Cancer Centre Karolinska, Department of Oncology, Karolinska University Hospital Solna, Stockholm, Sweden
    Ann Oncol 19:411-9. 2008
    ..The purpose of this report was to review issues associated with the introduction of alternative versions of biosimilars used in the oncology setting...
  17. ncbi 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
    Judith A Whitworth
    John Curtin School of Medical Research, Australian National University, Canberra, Australia
    J Hypertens 21:1983-92. 2003
    ....
  18. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  19. pmc Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle
    R S Taylor
    Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT
    BMJ 329:972-5. 2004
  20. pmc The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs
    Chi Liang Chen
    The Department of Accounting, The College of Business, Chung Yuan Christian University, Chung Li City, Taoyuan County 320, Taiwan
    BMC Public Health 8:118. 2008
    ..This research also demonstrates the use of micro-level longitudinal data to generate policy-relevant information. The research can be used to improve efficiency of health care resource use...
  21. pmc Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment
    Amy S Nunn
    Department of Population and International Health, Harvard School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 4:e305. 2007
    Little is known about the long-term drug costs associated with treating AIDS in developing countries. Brazil's AIDS treatment program has been cited widely as the developing world's largest and most successful AIDS treatment program...
  22. pmc What essential medicines for children are on the shelf?
    Jane Robertson
    University of Newcastle, Callaghan, NSW, Australia
    Bull World Health Organ 87:231-7. 2009
    ..To document the inclusion of key medicines for children in national essential medicines lists (EMLs) and standard treatment guidelines, and to assess the availability and cost of these medicines in 14 countries in central Africa...
  23. ncbi Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Mark Sculpher
    Centre for Health Economics, University of York, York, UK
    Value Health 8:433-46. 2005
    ....
  24. ncbi Impact of European pharmaceutical price regulation on generic price competition: a review
    Jaume Puig-Junoy
    Research Centre for Economics and Health CRES, Department of Economics and Business, Universitat Pompeu Fabra, Barcelona, Spain
    Pharmacoeconomics 28:649-63. 2010
    ....
  25. ncbi Healthcare costs and obesity prevention: drug costs and other sector-specific consequences
    David R Rappange
    Erasmus University Medical Centre, Department of Health Policy and Management and Institute for Medical Technology Assessment, Rotterdam, The Netherlands
    Pharmacoeconomics 27:1031-44. 2009
    ..Sector-specific financial consequences of preventing obesity are less well documented, for pharmaceutical spending as well as for other healthcare segments...
  26. ncbi American Society of Clinical Oncology guidance statement: the cost of cancer care
    Neal J Meropol
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 27:3868-74. 2009
    ..Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care...
  27. ncbi Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma
    Renato Ariano
    Allergy and Clinical Immunology Unit, General Hospital, Bordighera, Italy
    Allergy Asthma Proc 27:159-63. 2006
    ..These findings confirm some previous observations in studies from Germany and the United States that subcutaneous immunotherapy has significant economic advantages over antiallergic drug treatment in the long term...
  28. ncbi Cost-related medication underuse: do patients with chronic illnesses tell their doctors?
    John D Piette
    Department of Veterans Affairs Center for Practice Management and Outcomes Research, University of Michigan, Ann Arbor 48113 0170, USA
    Arch Intern Med 164:1749-55. 2004
    ..Although many chronically ill patients underuse prescription medications because of cost concerns, we know little about their discussions with clinicians about this issue...
  29. ncbi The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis
    F Borgstrom
    Medical Management Centre, Karolinska Institute, Stockholm, Sweden
    Osteoporos Int 21:339-49. 2010
    ..At a willingness-to-pay of pound 30,000 per quality-adjusted life-year (QALY), strontium ranelate was generally cost-effective in women with prior fracture at the threshold of osteoporosis from an age of 65 years...
  30. ncbi Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002
    Karolina Andersson
    Department of Social Medicine, Sahlgrenska Academy at Goteborg University, P O Box 453, SE 405 30 Goteborg, Sweden
    Health Policy 79:231-43. 2006
    ....
  31. pmc Cost-utility of aspirin and proton pump inhibitors for primary prevention
    Stephanie R Earnshaw
    RTI Health Solutions, Research Triangle Park, North Carolina 27709, USA
    Arch Intern Med 171:218-25. 2011
    ..Proton pump inhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding...
  32. ncbi Direct health care costs of diabetic patients in Spain
    Juan Oliva
    Department of Economics, University Carlos III de Madrid, Getafe, Madrid, Spain
    Diabetes Care 27:2616-21. 2004
    ..The goal of this study was to estimate the health care resources spent by type 1 and type 2 diabetic patients in Spain during the year 2002...
  33. ncbi Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity
    Donald D Sin
    Institute of Health Economics, Department of Medicine, University of Alberta, Edmonton, Canada
    Am J Med 116:325-31. 2004
    ..Inhaled corticosteroids reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD), but their cost-effectiveness is not known...
  34. ncbi The effect of generic competition on the price of brand-name drugs
    Joel Lexchin
    Emergency Department, University Health Network, Toronto, Ont, Canada
    Health Policy 68:47-54. 2004
    ..Literature from the US has shown that brand-name manufacturers do not compete on price once generic competitors become available. This study was undertaken to investigate if this is also true in Canada...
  35. ncbi Prescription drug costs and the generic dispensing ratio
    Joshua N Liberman
    CVS Caremark, 11311 McCormick Rd, Hunt Valley, MD 21031, USA
    J Manag Care Pharm 16:502-6. 2010
    ..Higher GDRs are considered important because they consistently produce lower prescription drug costs.
  36. ncbi Does the market share of generic medicines influence the price level?: a European analysis
    Pieter Dylst
    Research Centre for Pharmaceutical Care and Pharmaco economics, K U Leuven, Belgium
    Pharmacoeconomics 29:875-82. 2011
    ..This process generates savings to the healthcare payer and to patients, but knowledge about the factors affecting price competition in the pharmaceutical market following patent expiry is still limited...
  37. ncbi European countries with small populations can obtain low prices for drugs: Lithuania as a case history
    Kristina Garuoliene
    Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, University of Vilnius, MK Čiurlionio g 21 27, Vilnius, Lithuania
    Expert Rev Pharmacoecon Outcomes Res 11:343-9. 2011
    ..Assess whether European countries with smaller populations can obtain appreciable discounts for generics, similar to some of the larger European countries, to investigate the validity of recently published hypotheses...
  38. ncbi Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack
    Hooman Kamel
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
    Stroke 43:881-3. 2012
    ..The cost-effectiveness of dabigatran for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack has not been directly assessed...
  39. ncbi Potential clinical and economic impact of nonadherence with osteoporosis medications
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Calcif Tissue Int 86:202-10. 2010
    ..Adherence therefore remains an important challenge for health-care professionals treating osteoporosis...
  40. ncbi Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI
    Lizheng Shi
    School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA
    Value Health 13:28-33. 2010
    ..guidelines available in the literature or promulgated in many countries are either vague or silent about how drug costs should be established or measured so an international comparison of cost-effectiveness analysis (CEA) results ..
  41. ncbi Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system
    P Clark
    Clinical Epidemiology Unit, CMN Siglo XXI IMSS, Faculty of Medicine UNAM, Mexico City, Mexico
    Osteoporos Int 19:269-76. 2008
    ..We conclude that the economic burden due to the direct costs of hip fracture justifies wide-scale prevention programs for osteoporosis (OP)...
  42. ncbi [Assessment of the pharmaceutical expenditure in Hungary]
    András Inotai
    Semmelweis Egyetem, Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet, Budapest, Hogyes E u 9 1092
    Acta Pharm Hung 80:162-72. 2010
    ..In order to improve the allocative efficiency of health care spending, available resources should be spent only on effective, cost-effective, economically affordable medicines...
  43. ncbi Controlling the cost of innovative cancer therapeutics
    Nafees N Malik
    Institute of Biotechnology, University of Cambridge, Cambridge, UK
    Nat Rev Clin Oncol 6:550-2. 2009
    ..This article discusses what the impact of these strategies would be in terms of their ability to reduce costs and their effect on innovative cancer drug discovery...
  44. ncbi Availability, affordability, and prescribing pattern of medicines in Sudan
    Abdol Majid Cheraghali
    Department of Pharmacology, Baqiyatallah Medical Science University, 19945 Tehran, Iran
    Pharm World Sci 31:209-15. 2009
    ..To evaluate availability, affordability and prescribing pattern of medicines in both public and private health sectors of Sudan...
  45. ncbi Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience
    Y J Chou
    National Yang Ming University, Taipei, Taiwan
    Health Policy Plan 18:316-29. 2003
    ..We also found that the policy has practically no effect on clinics that have on-site pharmacists...
  46. ncbi Intervention research in rational use of drugs: a review
    A Le Grand
    Health Policy Plan 14:89-102. 1999
    ..In order to provide technical support and coordination of future intervention research the establishment of an international resource centre for drug use intervention research is recommended...
  47. ncbi Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II
    Louis P Garrison
    University of Washington, Seattle, WA 98195 7630, USA
    Value Health 13:8-13. 2010
    ..Society for Pharmacoeconomics and Outcomes Research [ISPOR] Task Force on Good Research Practices-Use of Drug Costs for Cost Effectiveness Analysis [Drug Cost Task Force (DCTF)]) was to review the definition of this perspective, ..
  48. pmc Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D
    Jeanne M Madden
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, 133 Brookline Ave, 6th Floor, Boston, Massachusetts 02215, USA
    JAMA 299:1922-8. 2008
    ..Cost-related medication nonadherence (CRN) has been a persistent problem for individuals who are elderly and disabled in the United States. The impact of Medicare prescription drug coverage (Part D) on CRN is unknown...
  49. ncbi Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema
    L Wilson
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 94143 0622, USA
    Respir Med 94:204-13. 2000
    ..More attention to healthcare management of chronic bronchitis and emphysema is suggested, and improving inhaler and anti-smoking compliance might be important targets...
  50. ncbi Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals
    Karolina Andersson
    Social Medicine, Department of Public Health and Community Medicine, Sahlgrenska Academy at Goteborg University, P O Box 453, SE 405 30 Goteborg, Sweden
    Health Policy 81:376-84. 2007
    ..This suggests that generic substitution has contributed to a reduction in the growth of pharmaceutical expenditure...
  51. ncbi Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada
    Douglas Coyle
    Ottawa Health Research Institute, Ottawa Hospital, Ottawa, Ontario, Canada
    Can J Cardiol 20:71-9. 2004
    ....
  52. ncbi Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
    David Coetzee
    Infectious Disease Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory 7925, South Africa
    AIDS 18:887-95. 2004
    ....
  53. ncbi Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications
    Brian Godman
    Institute for Pharmacological Research Mario Negri, Via Giuseppe La Masa 19, 20156 Milan, Italy
    Expert Rev Pharmacoecon Outcomes Res 10:707-22. 2010
    ..The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons...
  54. ncbi A comparative study of European rare disease and orphan drug markets
    Alain Denis
    Yellow Window Management Consultants, Antwerp, Belgium
    Health Policy 97:173-9. 2010
    ..This article aims to compare regulatory aspects of rare disease and orphan drug markets in Belgium, France, Italy, the Netherlands, Sweden and the United Kingdom...
  55. ncbi [Sustainability of Brazilian policy for access to antiretroviral drugs]
    Alexandre Grangeiro
    Instituto de Saude, Secretaria de Estado da Saúde, Rua Santo Antonio 590, 01314 000 São Paulo, SP, Brazil
    Rev Saude Publica 40:60-9. 2006
    ..The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008)...
  56. ncbi The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis
    Rachel Halpern
    Health Economics and Outcomes Research, i3 Innovus, 12125 Technology Dr, MN002 0258, Eden Prairie, MN 55344, USA
    J Manag Care Pharm 17:25-39. 2011
    ..Poor adherence to osteoporosis medications is associated with higher general burden of illness compared with optimal adherence...
  57. ncbi Ministry of Health's spending on drugs: program trends from 2002 to 2007
    Fabiola Sulpino Vieira
    Ministerio da Saude, Brasilia, DF, Brasil
    Rev Saude Publica 43:674-81. 2009
    ..To analyze the evolution of the Ministry of Health's spending on drugs...
  58. ncbi Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland
    Reeta Heikkilä
    Faculty of Health Sciences, School of Pharmacy, Social Pharmacy, University of Eastern Finland, Kuopio, Finland
    Pharmacoepidemiol Drug Saf 20:185-91. 2011
    ..We aimed to study the opinions and attitudes of Finnish people about GS five years after it was introduced, the reasons for substituting and what people think about generic medicines...
  59. ncbi Incorporating adherence into health economic modelling of osteoporosis
    O Strom
    i3 Innovus, Vasagatan 38 2 tr, 111 20, Stockholm, Sweden
    Osteoporos Int 20:23-34. 2009
    ..Important variables were the magnitude of drug effect, drug price, and fracture-related costs...
  60. pmc Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up
    Simon Brooker
    Department of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Health Policy Plan 23:24-35. 2008
    ..70-9.51). Independent variables were shown to be statistically associated with both sets of estimates. This study highlights the potential bias in transferring data across settings without understanding the nature of observed variations...
  61. pmc Manslaughter by fake artesunate in Asia--will Africa be next?
    Paul N Newton
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, United Kingdom
    PLoS Med 3:e197. 2006
  62. ncbi Prescription drug cost sharing: associations with medication and medical utilization and spending and health
    Dana P Goldman
    Health Economics, Finance, and Organization, RAND, Santa Monica, California 90407 2138, USA
    JAMA 298:61-9. 2007
    ..Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them...
  63. pmc Direct costs of chronic obstructive pulmonary disease among managed care patients
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 5:341-9. 2010
    ..To estimate patient- and episode-level direct costs of chronic obstructive pulmonary disease (COPD) among commercially insured patients in the US...
  64. pmc Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
    Sebastian Schneeweiss
    Department of Epidemiology, Harvard School of Public Health, Boston, Mass, USA
    CMAJ 166:737-45. 2002
    ..The objective of this study was to analyze the effect of reference-based pricing of angiotensin-converting enzyme (ACE) inhibitors on drug utilization, cost savings and potential substitution with other medication classes...
  65. ncbi The economics of effective AIDS treatment in Thailand
    Mead Over
    Center for Global Development, 1776 Massachusetts Avenue NW, Washington, DC 20036, USA
    AIDS 21:S105-16. 2007
    ..This paper projects the cost effectiveness, the affordability and the future fiscal burden of NAPHA to the government of Thailand under several different policy scenarios until the year 2025...
  66. ncbi Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02120, USA
    Clin Pharmacol Ther 74:388-400. 2003
    ....
  67. ncbi Pharmaceutical risk-sharing agreements
    Joseph P Cook
    NERA Economic Consulting, White Plains, NY, USA
    Pharmacoeconomics 26:551-6. 2008
    ..While there may be difficulties in devising such schemes for every product, such risk-sharing plans may become a staple feature of the market in the future...
  68. ncbi Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
    M Ekman
    1i3 Innovus, Stockholm, Sweden
    J Hum Hypertens 22:845-55. 2008
    ..The results from the model indicate that irbesartan provides a cost-effective antihypertensive treatment strategy compared with both placebo, and to valsartan and losartan...
  69. ncbi Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006)
    S Liatis
    First Department of Internal Medicine, Athens university medical school and diabetes center, Laiko Hospital, 17 Ag Thoma, 11527 Athens, Greece
    Exp Clin Endocrinol Diabetes 117:505-10. 2009
    ..This improvement, however, was associated with a considerable increase in the cost of medications prescribed for treatment of these parameters...
  70. pmc Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]
    Oguz Karabay
    Department of Infectious Disease and Clinical Microbiology, Abant Izzet Baysal University Izzet Baysal Medical Faculty Hospital, Bolu Turkey
    BMC Infect Dis 4:18. 2004
    ..The aim of the present study was to investigate the efficacy, adverse effects and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis...
  71. ncbi Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs
    John Hsu
    Center for Health Policy Studies and the Division of Research, Kaiser Permanente Medical Care Program, 2000 Broadway, Third Floor, Oakland, California 94612, USA
    JAMA 299:1929-36. 2008
    ..Medicare Part D drug benefits include substantial cost sharing...
  72. ncbi Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives
    Dirceu B Greco
    Internal Medicine Department, School of Medicine, Federal University of Minas Gerais, Avenida Alfredo Balena 190, CEP 30130 100 Belo Horizonte, MG, Brazil
    AIDS 21:S37-45. 2007
    ..The Brazilian AIDS Programme success is recognized worldwide, due to its integrated approach of prevention, respect for human rights and to free of charge universal access to state of the art antiretrovirals...
  73. ncbi Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs
    Martin Bach Jensen
    Research Unit for General Practice in The North Jutland Region and School of Public Health, Aarhus University, and Department of Clinical Epidemiology, Aarhus University Hospital, Algade 11, 9300 Sæby, Denmark
    Dan Med J 60:A4557. 2013
    ..The present study compared health care-related costs and the use of social benefits and transfer payments in participants with and without chronic obstructive pulmonary disease (COPD), and related the costs to the severity of the COPD...
  74. ncbi Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold
    Amber Cronk
    Department of Pharmacy, Kaiser Permanente Colorado, Aurora, CO 80011 9045, USA
    Am J Health Syst Pharm 65:1062-70. 2008
    ..The mechanisms used by Medicare beneficiaries who reached their Part D drug-benefit threshold to cope with the costs of prescription drugs were evaluated...
  75. ncbi Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension
    Richard Fiscella
    Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Drugs Aging 23:39-47. 2006
    ..The objective of the present study was to compare the cost effectiveness of bimatoprost with that of latanoprost in the treatment of glaucoma and ocular hypertension...
  76. ncbi Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals
    Theodore K Marras
    Department of Medicine, University of Toronto, Canada
    Can Respir J 11:131-7. 2004
    ..Evidence supporting antibiotic treatment guidelines and respiratory quinolones (RQs) in community-acquired pneumonia (CAP) is limited...
  77. ncbi [Price differences between generic and innovator medicines in Brazil]
    Fabiola Sulpino Vieira
    Centro Paulista de Economia da Saúde, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brasil
    Rev Saude Publica 40:444-9. 2006
    ..To assess the magnitude of price difference between generic and innovator medicines and to evaluate the effect of the price competition between them...
  78. ncbi Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations
    Patrick Lefebvre
    Groupe d Analyse, Ltee, Montreal, Quebec, Canada
    Curr Med Res Opin 22:1623-31. 2006
    ..To investigate the dosing patterns and treatment costs of erythropoietic agents in adult (>or= 18 years of age) cancer patients newly initiated on epoetin alfa (EPO) or darbepoetin alfa (DARB) in managed care organizations...
  79. ncbi Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database
    Francis Vekeman
    Groupe d Analyse, Ltee, Montreal, Quebec, Canada
    J Med Econ 12:1-8. 2009
    ..To understand current real-world utilisation of ESAs, this study examined epoetin alfa (EPO) and darbepoetin alfa (DARB) treatment patterns (dosing and treatment duration), dose ratio and ESA treatment costs...
  80. pmc Drug policy down under: Australia's pharmaceutical benefits scheme
    Stephen J Duckett
    La Trobe University, Victoria, Australia
    Health Care Financ Rev 25:55-67. 2004
    ..It incorporates patient copayments (with differentials for the general population compared with concessional beneficiaries). Prior to listing a drug on the PBS it is subject to a rigorous cost-effectiveness analysis...
  81. ncbi The relationship between body weight and drug costs: An Italian population-based study
    Ezio Degli Esposti
    Clinical Effectiveness Unit, Santa Maria delle Croci Hospital, Ravenna, Italy
    Clin Ther 28:1472-81. 2006
    ....
  82. ncbi Impact of telephone medication therapy management on medication and health-related problems, medication adherence, and Medicare Part D drug costs: a 6-month follow up
    Leticia R Moczygemba
    Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298 0533, USA
    Am J Geriatr Pharmacother 9:328-38. 2011
    ..As MTM programs evolve, evaluation is necessary to help inform MTM best practices...
  83. ncbi Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults
    D Price
    Department of General Practice and Primary Care, University of Aberdeen, Foresterhill Health Centre, Aberdeen, UK
    Clin Exp Allergy 35:282-7. 2005
    ..Asthma and allergic rhinitis (AR) frequently coexist, but have usually been studied separately in health economic analyses...
  84. ncbi Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations
    Malcolm Maclure
    School of Health Information Science, University of Victoria, Victoria, British Columbia, Canada
    Med Care 45:S44-9. 2007
    ..Centralized administrative databases enable low-cost pragmatic randomized trials (PRTs) of drug effectiveness and safety. We simplified the PRT strategy by using designed delays (DD) to evaluate drug policies...
  85. ncbi [Availability of generic drugs in the public sector and prices in the private sector in different regions of Brazil]
    Elaine Silva Miranda
    Escola Nacional de Saude Publica Sergio Arouca, Fundacao Oswaldo Cruz, Rio de Janeiro, Brasil
    Cad Saude Publica 25:2147-58. 2009
    ..It is estimated that price competition is occurring among bioequivalent generic drugs and between them and multisource products for the same substance, but not with reference brands...
  86. pmc Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 6:13-22. 2011
    ....
  87. ncbi Generic utilization and cost-sharing for prescription drugs
    Teresa Bernard Gibson
    Thomson Reuters, Ann Arbor, MI, USA
    Adv Health Econ Health Serv Res 22:195-219. 2010
    ....
  88. ncbi Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia
    Carrie W Nemerovski
    University of Michigan Hospitals and Health Centers UMHHC, Ann Arbor, MI, USA
    Am J Health Syst Pharm 67:295-9. 2010
    b>Drug costs and utilization after implementation of a posaconazole prophylaxis protocol in adults with acute myelogenous leukemia (AML) were studied.
  89. ncbi Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications
    Robert J Noecker
    Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Am J Ophthalmol 141:S15-21. 2006
    ..Cost-effectiveness evaluation of monotherapy with the newer lipid class of intraocular pressure (IOP)-lowering medications in glaucoma and ocular hypertension...
  90. ncbi Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis
    Leslie Jackson Conwell
    Mathematica Policy Research, Inc, Washington, DC, USA
    Am J Geriatr Pharmacother 9:241-9. 2011
    ..Because osteoporosis has a relatively high prevalence among Medicare-eligible postmenopausal women, we examined changes in utilization of osteoporosis medications during this coverage gap...
  91. ncbi Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study
    Pearl D Gumbs
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceuticals Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Drugs Aging 23:733-41. 2006
    ..However, several studies have established both undertreatment and non-guidelines-indicated treatment with statins, suggesting a suboptimal use of resources...
  92. ncbi Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Dr, Bide West, Mail Stop B 3153, Research Triangle Park, NC 27709, USA
    Respir Med 106:829-37. 2012
    ..To determine clinical and economic outcomes following COPD-related hospitalization/emergency department (ED) care in patients receiving COPD maintenance therapy...
  93. pmc Household expenditures for medicines and the role of free medicines in the Brazilian public health system
    Andrea D Bertoldi
    Programa de Pós Graduação em Saúde Coletiva, Universidade do Vale do Rio dos Sinos, Sao Leopoldo, Brazil
    Am J Public Health 101:916-21. 2011
    ..We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system...
  94. ncbi Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance's Global Budget Program in Taiwan
    Chih Chieh Chou
    Department of Family and Community Health, Tri Service General Hospital, Taipei, Taiwan
    Med Sci Monit 14:PH33-39. 2008
    ..To examine changes in medicine utilization and prescription trends for diabetic (DM) and hypertensive (HT) patients upon initiation of the National Health Insurance (NHI) global budget (GB) program in Taiwan...
  95. pmc Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy
    Joe T R Clarke
    Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Toronto, Ont
    CMAJ 174:189-90. 2006
  96. ncbi Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Megan E Coombes
    Centre for Health Services and Policy Research, University of British Columbia, 429 2194 Health Sciences Mall, Vancouver, BC V6T 1Z3
    Healthc Q 7:suppl 13-9. 2004
    ..A national standard for "reasonable" catastrophic coverage has yet to be formally defined...
  97. ncbi Pharmacoeconomics--an aid to better decision-making
    R Arenas-Guzman
    Calz de Tlalpan 4800, Col Toriello Guerra, Mexico
    J Eur Acad Dermatol Venereol 19:34-9. 2005
    ..The second aim was to review pharmacoeconomic studies in the field of onychomycosis and finally to discuss future perspectives...
  98. ncbi A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry
    Aj Owen
    Centre for Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
    J Med Econ 11:235-43. 2008
    ..Risk-sharing schemes between drug sponsor and government may provide an acceptable method of balancing the uncertainty of longer-term cost effectiveness with the public demand for equitable and timely access to new drugs...
  99. pmc Medicaid drugs
    John A Poisal
    Centers for Medicare and Medicaid Services, 7500 Security Boulevard, C3 16 27, Baltimore, MD 21244 1850, USA
    Health Care Financ Rev 25:1-4. 2004
    ..Specifically, in this issue, you will find comprehensive analyses of drug expenditure trends, issues regarding access to pharmaceuticals in Medicaid, and an evaluation of ongoing generic drug cost-containment programs...
  100. ncbi Many new cancer drugs in the United Kingdom are facing negative NICE rulings
    Eric Low
    J Clin Oncol 25:2635-6; author reply 2637-8. 2007
  101. pmc Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
    Arna S Desser
    Department of Health Management and Health Economics, University of Oslo, PO Box 1089, Blindern, N 0317 Oslo, Norway
    BMJ 341:c4715. 2010
    ..To determine whether a general societal preference for prioritising treatment of rare diseases over common ones exists and could provide a justification for accepting higher cost effectiveness thresholds for orphan drugs...

Research Grants71

  1. Drug Cost Containment Changes and Quality of Care for Mentally Ill Dual Enrollees
    Stephen B Soumerai; Fiscal Year: 2012
    ..therapy from Medicaid prior authorization (PA), while PDPs often use PA as the primary approach for managing drug costs. Thus, as drug coverage responsibility shifts from states to private plans, dually enrolled beneficiaries face ..
  2. Continuous Countercurrent Tangential Chromatography
    Oleg Shinkazh; Fiscal Year: 2011
    ..health by decreasing time to market and reducing production costs, both of which will lead to a reduction in drug costs. Chromatan projects a fifth year market peneratraion of 10% and revenues of $100 million...
  3. Sustainable Financial Incentives To Improve Prescription Practices For Malaria
    WENDY PRUDHOMME O'MEARA; Fiscal Year: 2013
    ..Although there is considerable incentive for governments to reduce drug costs and wastage, the financial pressure is not experienced at the appropriate levels of decision- making...
  4. Tanslating Research into Action for Diabetes (TRIAD) Legacy Study
    Carol M Mangione; Fiscal Year: 2012
    ..beneficiaries with diabetes in the Part D program;5) To compare the out-of-pocket medication costs, total drug costs, and adherence to chronic medications for beneficiaries in Low Income Qualifier (LIQ) versus commercial plans ..
  5. Optical Coherence Tomography Based Freeze Drying Microscopy
    Mircea Mujat; Fiscal Year: 2010
    ..temperature determinations which lead to longer processing times, wasted resources and increased production and drug costs. The development of biological drugs often requires product formulations that must be lyophilized to produce ..
  6. Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's Dis
    Nurulain T Zaveri; Fiscal Year: 2010
    ..The annual cost burden of PD is estimated at $35 billion, in combined medical and drug costs, patient care and indirect costs of loss of productivity...
  7. Optical Coherence Tomography Based Freeze Drying Microscopy
    Mircea Mujat; Fiscal Year: 2013
    ..eliminates errors in Tc determinations which will lead to shorter processing times and reduced production and drug costs. Biological drugs often require lyophilization to produce stable products that are stored in vials and ..
  8. Racial and Ethnic Differences in Response to the Medicare Coverage Gap among Pati
    Yuting Zhang; Fiscal Year: 2012
    ..gap, because almost half of them will reach the coverage gap and will reduce their medication use due to high drug costs. Cost-related medication non-adherence worsens health outcomes, and increased rates of hospitalization and total ..
  9. Reducing Cost-Related Medication Nonadherence in Persons with Diabetes
    Chien Wen Tseng; Fiscal Year: 2011
    ..PrescribingGuide.com improves medication adherence and lowers drug costs for persons with diabetes by helping physicians easily know drug costs when prescribing...
  10. The Coverage Gap and Clinical Outcomes in a Medicare Advantage Part D Population
    Obidiugwu Kenrik Duru; Fiscal Year: 2012
    ..with diabetes based on prescription fills for an anti- glycemic medication, and use prescription claims to track drug costs and determine dates of gap entry and gap exit...
  11. Impact of Medicare Drug Coverage on Antidepressant Quality and Outcomes
    SEBASTIAN G SCHNEEWEISS; Fiscal Year: 2010
    ..mainstay of treatment for depressed elderly, regimens are often problematic and undermined by high prescription drug costs. The new Medicare drug benefit represents an unprecedented opportunity to address these costs;however there are ..
  12. Phase II Commercialization of Continuous Countercurrent Tangential Chromatography
    Oleg Shinkazh; Fiscal Year: 2013
    ..will improve public health by decreasing time to market and reducing production costs, both of which will lead to a reduction in drug costs. Chromatan projects a fifth year market penetration of 10% and revenues of $50 million.
  13. Postmarketing Surveillance of Generic Drug Usage and Substitution Patterns
    Ilene H Zuckerman; Fiscal Year: 2013
    ..Congressional Budget Office estimates that generic substitution under Medicare Part D reduced total prescription drug costs for Medicare beneficiaries in 2007 by $33 billion, 55% lower than if no generic substitution had occurred...
  14. Health Implications of MTM Eligibility Criteria
    JUNLING NONE WANG; Fiscal Year: 2013
    ..and racial and ethnic minorities historically tend to use fewer prescription drugs and incur lower prescription drug costs than do Whites...
  15. Demonstration of Quality Improvement of Medication Therapy Management Services
    William R Doucette; Fiscal Year: 2012
    ..therapy), use of diabetes medications, use of high risk medications, duplication of therapy, and average monthly drug costs. The repeated measures design will permit comparisons on the MTM performance measures created from drug and MTM ..
  16. Comparative Effectiveness of Prophylaxis in Cataract Surgery
    Lisa J Herrinton; Fiscal Year: 2013
    ..pre-operative antibiotic administrations can be eliminated, we calculate potential savings of ~$70 per case in drug costs alone, totaling $127 million annual savings to Medicare...
  17. Companion Diagnostic for Multiple Myeloma
    Michael G Zwick; Fiscal Year: 2013
    ..Unfortunately no such test exists for multiple myeloma, and the associated drug costs and side effects are quite significant...
  18. Dissertation Support: Whose $800 Billion? Risk Adjusted Subsidies in Medicare Pa
    COLLEEN MARIE CAREY; Fiscal Year: 2012
    ..Medicare then pays the insurance plans a subsidy worth, in expectation, 75% of drug costs. Any beneficiary can enroll in a given Part D plan at the same premium, regardless of health status;insurers are ..
  19. Differences In Incentives Between Stand Alone Medicare Drug Coverage vs Medicare
    Kosali Ilayperuma Simon; Fiscal Year: 2010
    ..than PDPs to decrease the formulary generosity of drugs whose use signals that the patient also has high non-drug costs, during open enrollment periods when such potential enrollees can be discouraged from enrolling and current ..
  20. Consequences of Drug Cost Sharing:A New Randomized Trial
    Sebastian Schneeweiss; Fiscal Year: 2006
    ..S. health plans to contain drug costs. In our current AHRQ study we showed that a province wide DCS policy in British Columbia, Canada, was successful ..
  21. Drug Coverage and Cost Offsets: Two-Part Models with Endogenous Treatment Effects
    JOSEPH TERZA; Fiscal Year: 2009
    DESCRIPTION (provided by the applicant): Prescription drug costs are the fastest rising component of national health expenditures over the last half decade and are projected to significantly outpace other service sectors for at least ..
  22. Effects of income-based drug charges on older Patients
    Sebastian Schneeweiss; Fiscal Year: 2006
    DESCRIPTION (provided by investigator): Policies to contain prescription drug costs in the elderly are widely debated because they will impact heavily on the health of older Americans as well as affect the fundability of federal and ..
  23. Prescription Drug Cost-sharing: Affordability/Safety
    John Hsu; Fiscal Year: 2005
    DESCRIPTION: (Provided by applicant) Cost-sharing is a commonly used mechanism to control prescription drug costs; there is, however, a lack of information on how drug cost-sharing affects clinical outcomes and total medical costs, which ..
  24. Remibursement Limits, Antidepressants, and Outcomes
    Philip Wang; Fiscal Year: 2005
    Income-based deductibles (IBDs) for prescription drugs require elderly patients to pay all drug costs up to an amount determined by their incomes; this approach has been proposed for containing costs in a potential Medicare drug benefit ..
  25. Remibursement Limits, Antidepressants, and Outcomes
    Sebastian Schneeweiss; Fiscal Year: 2007
    Income-based deductibles (IBDs) for prescription drugs require elderly patients to pay all drug costs up to an amount determined by their incomes; this approach has been proposed for containing costs in a potential Medicare drug benefit ..
  26. INFLUENCE OF TRIPLICATE POLICY ON NARCOTIC UTILIZATION
    Linda Simoni Wastila; Fiscal Year: 1992
    ..a differential impact on prescribing patterns in MCPP states relative to non-MCPP states? In response to rising drug costs and the problem of prescription drug abuse and misuse, state and federal governments are increasing scrutiny of ..
  27. Understanding How Insurance Affects Persons with Multip*
    Matthew Solomon; Fiscal Year: 2003
    ..As drug costs have grown, access to drugs has decreased for both the insured and uninsured...
  28. A Novel System for Producing Pharmaceutical Proteins
    William Petersen; Fiscal Year: 2006
    ..Rxoa Biosciences is developing a novel plant-based production system to increase protein production capacity and reduce overall protein drug costs. [unreadable] [unreadable]
  29. Precancerous Mammary Transcriptome in Mice after Estrog*
    Teresa Rose Hellekant; Fiscal Year: 2006
    ..Clearly more drug development is needed, but the pace is slow and costs are high, contributing to high patient drug costs. One way to promote faster and more cost-effective drug development is through the identification of the ..
  30. Effect of a Restrictive Formulary on Low Income Children
    JULIE URMIE; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Faced with rapidly rising prescription drug costs, public and private health insurance programs need to manage these costs while still providing access to necessary prescription drug ..
  31. Out-of-Pocket Prescribed Drug Costs Among Elderly Women
    Usha Sambamoorthi; Fiscal Year: 2002
    ..abstract_text> ..
  32. Clinical Trial Identification Program
    STEVEN HOGE; Fiscal Year: 2004
    ..the benefits of innovative treatments and, when the treatments are available, bear the burden of higher drug costs. Second, in order to demonstrate safety and efficacy in all populations, diversity must be achieved in the ..
  33. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2011
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  34. Economics of Formulary Design and Mental Health Policy
    Haiden Huskamp; Fiscal Year: 2006
    ..The third project examines the effect of a three-tier formulary on psychotropic drug costs and utilization patterns in a retiree population and explores the impact of formularies on the mental health ..
  35. Antipsychotic use in children and adolescents
    NIKESH PATEL; Fiscal Year: 2004
    ..Secondary analyses to be included in this study will assess total Medicaid expenditures, including drug costs and health care service utilization...
  36. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  37. The Role of Customization in Psychotropic Prescribing
    Dominic Hodgkin; Fiscal Year: 2009
    ....
  38. Impact of 3 Tier Drug Copays on Use and Spending
    Dominic Hodgkin; Fiscal Year: 2003
    ..abstract_text> ..
  39. Specialty Mental Health Care--Expanding Access in an HMO
    Dominic Hodgkin; Fiscal Year: 2003
    ..The results will inform health plan decision-makers and others as they make utilization management choices that may have a major impact on patients and enrollee populations overall. ..
  40. FACTORS AFFECTING USE OF MEDICATION TO TREAT ALCOHOLISM
    TAMI MARK; Fiscal Year: 2001
    ..We propose to collect this information through experts panels and a national survey of physicians specialized in treating substance abuse. ..
  41. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  42. Cost-effectiveness of preventing HIV complications
    Kenneth Freedberg; Fiscal Year: 2005
    ..Our aim, in the present proposal, is to exert an equally important impact in the years to come. ..
  43. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  44. Economic Evaluations of Emerging Genomic Tests for Early Stage Breast Cancer
    YA CHEN SHIH; Fiscal Year: 2008
    ..To estimate the budgetary impact of the emerging pharmacogenomic prognostic and/or predictive tests [unreadable] [unreadable] [unreadable]..
  45. POPULATION-BASED MANAGEMENT OF DEPRESSION
    Gregory Simon; Fiscal Year: 2003
    ..e. 12-18 mos) Incremental cost and cost-effectiveness of each intervention program compared to care as usual. ..
  46. PRICE INDEXES OF MENTAL HEALTH TREATMENT
    Richard Frank; Fiscal Year: 2002
    ..To assess outcomes we will use clinical literature along with three expert panels of clinician-researchers to rate expected outcomes for specific combinations of consumers and treatments. ..
  47. COST EFFECTIVENESS OF GENETIC SCREENING FOR COLON CANCER
    Scott Ramsey; Fiscal Year: 2002
    ....
  48. Epidemiology and Care of Comorbid Obesity and Depression
    Gregory Simon; Fiscal Year: 2006
    ..weight loss, nutrient intake, physical activity, depressive symptoms, functional impairment and disability in the two groups of women with comorbid obesity and depression randomly assigned to the two different intervention programs ..
  49. Can Longitudinal Population-Based Data Help to Personalize Depression Treatment?
    Gregory E Simon; Fiscal Year: 2010
    ..We propose a set of targeted methodologic studies to prepare for a multi-site research consortium focused on predicting response to specific depression treatments. ..
  50. Optimal Strategies for Management of HIV Disease
    Kenneth Freedberg; Fiscal Year: 2008
    ..Freedberg will create a multiplicative effect in increasing research capability in this important area of HIV-related patient-oriented investigation. ..
  51. Pilot Trial of Peer Support for Bipolar Disorder
    Gregory Simon; Fiscal Year: 2006
    ..abstract_text> ..
  52. Economic Impacts of New Drugs
    Sharon Lise Normand; Fiscal Year: 2006
    ..Finally, we will examine the proposition that offsets occur differentially across racial and ethnic groups, for high utilizers and according to the organization of insurance arrangements. [unreadable] [unreadable]..
  53. Modeling Adherence to Psychotherapy for Depression
    Gregory Simon; Fiscal Year: 2009
    ..The proposed research is one component of an ongoing comprehensive program to understand and increase consumer demand for effective depression treatment. ..
  54. A Genetic Screening Policy Model for Colorectal Cancer
    Scott Ramsey; Fiscal Year: 2006
    ..The model will incorporate QOL information from Aim 2, along with family history, clinical, and screening information from the Seattle CFR. ..
  55. Analyzing Vaccine Programs/Policies in Western Europe
    Gary Freed; Fiscal Year: 2004
    ..abstract_text> ..
  56. IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE
    Murray Stein; Fiscal Year: 2002
    ..abstract_text> ..
  57. Recurrence of T1D in Pancreas Transplantation
    George Burke; Fiscal Year: 2009
    ..The knowledge gained should also be relevant to islet cell transplantation and spontaneous disease. ..
  58. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  59. Computerized EMR-Assisted Smoking Cessation (CEASCE)
    Jennifer Haas; Fiscal Year: 2007
    ..Future Directions: Evaluate whether CEASCE can serve as a prototype for other common primary care problems that require counseling for behavior change. [unreadable] [unreadable]..
  60. Core symptoms and profiles in premenstrual syndrome
    Ellen Freeman; Fiscal Year: 2008
    ..Further information will contribute to improved health care for women in their reproductive years. [unreadable] [unreadable] [unreadable] [unreadable]..
  61. Gastric Tube Placement in Young Children
    Marsha Ellett; Fiscal Year: 2008
    ..Results from this study will increase the safety of using gastric tubes in young children. ..
  62. Pain Assessment Interview and Clinical Advisory System
    Stephen Butler; Fiscal Year: 2008
    ..Thus, we believe this product has enormous commercial viability and public health importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  63. Medication Management Decisions in Schizophrenia
    Mark Olfson; Fiscal Year: 2003
    ..The results will inform quality improvement programs by identifying key modifiable determinants of the quality of medication management in the community treatment of schizophrenia. ..
  64. Internet Monitoring Of Prescription Drug Abuse
    Stephen Butler; Fiscal Year: 2006
    ..Phase II will see development of a full prototype of PRISM and demonstration of its reliability and internal and external validity. [unreadable] [unreadable] [unreadable] [unreadable]..
  65. ASI-MV.net: A Prescription Medication Monitoring Tool
    Stephen Butler; Fiscal Year: 2006
    ..Phase II will fully develop the ASI-MV.net website and establish its reliability and validity. The ASI-MV.net will be an innovative solution to problems collecting product-specific addictions data in real time. [unreadable] [unreadable]..
  66. Computerized ASI Follow-up and Outcome System
    Stephen Butler; Fiscal Year: 2004
    ..Client acceptance will be evaluated along with correspondence between the IVR and traditional ASI administration. Phase II will evaluate the system's validity, capacity to produce acceptable response rates, and cost-effectiveness. ..
  67. Optimizing use of androgen deprivation therapy for prostate cancer
    Vahakn B Shahinian; Fiscal Year: 2010
    ..POP dominant) on care of men on ADT. ..
  68. ASSERTIVE COMMUNITY TREATMENT FOR THE DUALLY DIAGNOSED
    Robert Drake; Fiscal Year: 2004
    ..Finally, we will take maximal advantage of conducting the rural and urban studies in conjunction with one another. ..
  69. Medicare Study of Cost-sharing Ramifications and Prescription Drug Benefits
    John Hsu; Fiscal Year: 2009
    ..This study will be the first to examine the clinical and economic effects of new Medicare Part D plans, using comprehensive automated data from before and after the introduction of Part D, for a well- defined population. ..